Abaxis, Inc. (NASDAQ: ABAX) Stock Competitors & Peer Comparison
See ABAX's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Equipment & Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ABAX and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ABAX | $83.00 | +0.00% | 0 | 70.62 | $1.18 | +0.77% |
| SIRO | $109.97 | +0.00% | 22B | 31.88 | $3.45 | N/A |
| HIMS | $31.59 | +6.51% | 7B | -315.90 | -$0.10 | N/A |
| MMED | $19.60 | +6.41% | 5.5B | -25.29 | -$0.78 | N/A |
| OMCL | $36.81 | +1.80% | 1.7B | 19.27 | $1.91 | N/A |
| DRTS | $13.14 | +1.15% | 1.2B | -19.61 | -$0.67 | N/A |
| MLAB | $102.65 | +1.62% | 574.4M | 10.36 | $9.91 | +0.62% |
| LAB | $0.80 | -0.01% | 313.2M | -11.43 | -$0.07 | N/A |
| STXS | $1.42 | +4.41% | 139M | -8.35 | -$0.17 | N/A |
| FONR | $19.09 | +0.00% | 117.8M | 19.09 | $1.00 | N/A |
Stock Comparison
Sirona Dental Systems, Inc. (NASDAQ: SIRO)
ABAX vs SIRO Comparison August 2026
Abaxis, Inc. (NASDAQ: ABAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABAX stands at 0. In comparison, SIRO has a market cap of 22B. Regarding current trading prices, ABAX is priced at $83.00 on the NASDAQ, while SIRO trades at $109.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABAX currently has a P/E ratio of 70.62, whereas SIRO's P/E ratio is 31.88. In terms of profitability, ABAX's ROE is +0.10%, compared to SIRO's ROE of +0.14%. Regarding short-term risk, ABAX is less volatile compared to SIRO. This indicates lower risk in terms of short-term price fluctuations for ABAX.Check SIRO's competition here
Hims & Hers Health, Inc. (NYSE: HIMS)
ABAX vs HIMS Comparison August 2026
Abaxis, Inc. (NASDAQ: ABAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABAX stands at 0. In comparison, HIMS has a market cap of 7B. Regarding current trading prices, ABAX is priced at $83.00 on the NASDAQ, while HIMS trades at $31.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABAX currently has a P/E ratio of 70.62, whereas HIMS's P/E ratio is -315.90. In terms of profitability, ABAX's ROE is +0.10%, compared to HIMS's ROE of -0.02%. Regarding short-term risk, ABAX is less volatile compared to HIMS. This indicates lower risk in terms of short-term price fluctuations for ABAX.Check HIMS's competition here
MiniMed Group, Inc. Common Stock (NASDAQ: MMED)
ABAX vs MMED Comparison August 2026
Abaxis, Inc. (NASDAQ: ABAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABAX stands at 0. In comparison, MMED has a market cap of 5.5B. Regarding current trading prices, ABAX is priced at $83.00 on the NASDAQ, while MMED trades at $19.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABAX currently has a P/E ratio of 70.62, whereas MMED's P/E ratio is -25.29. In terms of profitability, ABAX's ROE is +0.10%, compared to MMED's ROE of -0.14%. Regarding short-term risk, ABAX is less volatile compared to MMED. This indicates lower risk in terms of short-term price fluctuations for ABAX.Check MMED's competition here
Omnicell, Inc. (NASDAQ: OMCL)
ABAX vs OMCL Comparison August 2026
Abaxis, Inc. (NASDAQ: ABAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABAX stands at 0. In comparison, OMCL has a market cap of 1.7B. Regarding current trading prices, ABAX is priced at $83.00 on the NASDAQ, while OMCL trades at $36.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABAX currently has a P/E ratio of 70.62, whereas OMCL's P/E ratio is 19.27. In terms of profitability, ABAX's ROE is +0.10%, compared to OMCL's ROE of +0.03%. Regarding short-term risk, ABAX is less volatile compared to OMCL. This indicates lower risk in terms of short-term price fluctuations for ABAX.Check OMCL's competition here
Alpha Tau Medical Ltd (NASDAQ: DRTS)
ABAX vs DRTS Comparison August 2026
Abaxis, Inc. (NASDAQ: ABAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABAX stands at 0. In comparison, DRTS has a market cap of 1.2B. Regarding current trading prices, ABAX is priced at $83.00 on the NASDAQ, while DRTS trades at $13.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABAX currently has a P/E ratio of 70.62, whereas DRTS's P/E ratio is -19.61. In terms of profitability, ABAX's ROE is +0.10%, compared to DRTS's ROE of -0.73%. Regarding short-term risk, ABAX is less volatile compared to DRTS. This indicates lower risk in terms of short-term price fluctuations for ABAX.Check DRTS's competition here
Mesa Laboratories, Inc. (NASDAQ: MLAB)
ABAX vs MLAB Comparison August 2026
Abaxis, Inc. (NASDAQ: ABAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABAX stands at 0. In comparison, MLAB has a market cap of 574.4M. Regarding current trading prices, ABAX is priced at $83.00 on the NASDAQ, while MLAB trades at $102.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABAX currently has a P/E ratio of 70.62, whereas MLAB's P/E ratio is 10.36. In terms of profitability, ABAX's ROE is +0.10%, compared to MLAB's ROE of +0.04%. Regarding short-term risk, ABAX is less volatile compared to MLAB. This indicates lower risk in terms of short-term price fluctuations for ABAX.Check MLAB's competition here
Standard BioTools Inc. (NASDAQ: LAB)
ABAX vs LAB Comparison August 2026
Abaxis, Inc. (NASDAQ: ABAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABAX stands at 0. In comparison, LAB has a market cap of 313.2M. Regarding current trading prices, ABAX is priced at $83.00 on the NASDAQ, while LAB trades at $0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABAX currently has a P/E ratio of 70.62, whereas LAB's P/E ratio is -11.43. In terms of profitability, ABAX's ROE is +0.10%, compared to LAB's ROE of -0.18%. Regarding short-term risk, ABAX is less volatile compared to LAB. This indicates lower risk in terms of short-term price fluctuations for ABAX.Check LAB's competition here
Stereotaxis, Inc. (AMEX: STXS)
ABAX vs STXS Comparison August 2026
Abaxis, Inc. (NASDAQ: ABAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABAX stands at 0. In comparison, STXS has a market cap of 139M. Regarding current trading prices, ABAX is priced at $83.00 on the NASDAQ, while STXS trades at $1.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABAX currently has a P/E ratio of 70.62, whereas STXS's P/E ratio is -8.35. In terms of profitability, ABAX's ROE is +0.10%, compared to STXS's ROE of -1.53%. Regarding short-term risk, ABAX is less volatile compared to STXS. This indicates lower risk in terms of short-term price fluctuations for ABAX.Check STXS's competition here
Fonar Corp. (NASDAQ: FONR)
ABAX vs FONR Comparison August 2026
Abaxis, Inc. (NASDAQ: ABAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABAX stands at 0. In comparison, FONR has a market cap of 117.8M. Regarding current trading prices, ABAX is priced at $83.00 on the NASDAQ, while FONR trades at $19.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABAX currently has a P/E ratio of 70.62, whereas FONR's P/E ratio is 19.09. In terms of profitability, ABAX's ROE is +0.10%, compared to FONR's ROE of +0.04%. Regarding short-term risk, ABAX is similarly volatile compared to FONR. This indicates similar risk in terms of short-term price fluctuations for ABAX.Check FONR's competition here
LENSAR Inc (NASDAQ: LNSR)
ABAX vs LNSR Comparison August 2026
Abaxis, Inc. (NASDAQ: ABAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABAX stands at 0. In comparison, LNSR has a market cap of 74.2M. Regarding current trading prices, ABAX is priced at $83.00 on the NASDAQ, while LNSR trades at $6.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABAX currently has a P/E ratio of 70.62, whereas LNSR's P/E ratio is 6.16. In terms of profitability, ABAX's ROE is +0.10%, compared to LNSR's ROE of -5.15%. Regarding short-term risk, ABAX is less volatile compared to LNSR. This indicates lower risk in terms of short-term price fluctuations for ABAX.Check LNSR's competition here
Kindly MD, Inc. (NASDAQ: KDLY)
ABAX vs KDLY Comparison August 2026
Abaxis, Inc. (NASDAQ: ABAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABAX stands at 0. In comparison, KDLY has a market cap of 68.1M. Regarding current trading prices, ABAX is priced at $83.00 on the NASDAQ, while KDLY trades at $11.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABAX currently has a P/E ratio of 70.62, whereas KDLY's P/E ratio is -15.48. In terms of profitability, ABAX's ROE is +0.10%, compared to KDLY's ROE of -0.85%. Regarding short-term risk, ABAX is less volatile compared to KDLY. This indicates lower risk in terms of short-term price fluctuations for ABAX.Check KDLY's competition here
NeueHealth, Inc. (NYSE: NEUE)
ABAX vs NEUE Comparison August 2026
Abaxis, Inc. (NASDAQ: ABAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABAX stands at 0. In comparison, NEUE has a market cap of 60.9M. Regarding current trading prices, ABAX is priced at $83.00 on the NASDAQ, while NEUE trades at $6.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABAX currently has a P/E ratio of 70.62, whereas NEUE's P/E ratio is -0.38. In terms of profitability, ABAX's ROE is +0.10%, compared to NEUE's ROE of +0.05%. Regarding short-term risk, ABAX is less volatile compared to NEUE. This indicates lower risk in terms of short-term price fluctuations for ABAX.Check NEUE's competition here
SANUWAVE Health Inc. (NASDAQ: SNWV)
ABAX vs SNWV Comparison August 2026
Abaxis, Inc. (NASDAQ: ABAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABAX stands at 0. In comparison, SNWV has a market cap of 50.6M. Regarding current trading prices, ABAX is priced at $83.00 on the NASDAQ, while SNWV trades at $5.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABAX currently has a P/E ratio of 70.62, whereas SNWV's P/E ratio is 17.82. In terms of profitability, ABAX's ROE is +0.10%, compared to SNWV's ROE of +17.28%. Regarding short-term risk, ABAX is less volatile compared to SNWV. This indicates lower risk in terms of short-term price fluctuations for ABAX.Check SNWV's competition here
Ekso Bionics Holdings, Inc. (NASDAQ: EKSO)
ABAX vs EKSO Comparison August 2026
Abaxis, Inc. (NASDAQ: ABAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABAX stands at 0. In comparison, EKSO has a market cap of 38.6M. Regarding current trading prices, ABAX is priced at $83.00 on the NASDAQ, while EKSO trades at $15.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABAX currently has a P/E ratio of 70.62, whereas EKSO's P/E ratio is -3.11. In terms of profitability, ABAX's ROE is +0.10%, compared to EKSO's ROE of -1.77%. Regarding short-term risk, ABAX is less volatile compared to EKSO. This indicates lower risk in terms of short-term price fluctuations for ABAX.Check EKSO's competition here
HeartBeam, Inc. (NASDAQ: BEAT)
ABAX vs BEAT Comparison August 2026
Abaxis, Inc. (NASDAQ: ABAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABAX stands at 0. In comparison, BEAT has a market cap of 29.1M. Regarding current trading prices, ABAX is priced at $83.00 on the NASDAQ, while BEAT trades at $0.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABAX currently has a P/E ratio of 70.62, whereas BEAT's P/E ratio is -0.94. In terms of profitability, ABAX's ROE is +0.10%, compared to BEAT's ROE of -10.34%. Regarding short-term risk, ABAX is less volatile compared to BEAT. This indicates lower risk in terms of short-term price fluctuations for ABAX.Check BEAT's competition here
Sharps Technology Inc. Wt (NASDAQ: STSSW)
ABAX vs STSSW Comparison August 2026
Abaxis, Inc. (NASDAQ: ABAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABAX stands at 0. In comparison, STSSW has a market cap of 839.4K. Regarding current trading prices, ABAX is priced at $83.00 on the NASDAQ, while STSSW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABAX currently has a P/E ratio of 70.62, whereas STSSW's P/E ratio is -0.03. In terms of profitability, ABAX's ROE is +0.10%, compared to STSSW's ROE of N/A. Regarding short-term risk, ABAX is similarly volatile compared to STSSW. This indicates similar risk in terms of short-term price fluctuations for ABAX.Check STSSW's competition here
Advisory Board Co. (The) (NASDAQ: ABCO)
ABAX vs ABCO Comparison August 2026
Abaxis, Inc. (NASDAQ: ABAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABAX stands at 0. In comparison, ABCO has a market cap of 0. Regarding current trading prices, ABAX is priced at $83.00 on the NASDAQ, while ABCO trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABAX currently has a P/E ratio of 70.62, whereas ABCO's P/E ratio is 0.52. In terms of profitability, ABAX's ROE is +0.10%, compared to ABCO's ROE of +0.19%. Regarding short-term risk, ABAX is less volatile compared to ABCO. This indicates lower risk in terms of short-term price fluctuations for ABAX.Check ABCO's competition here
Surgical Care Affiliates, Inc. (NASDAQ: SCAI)
ABAX vs SCAI Comparison August 2026
Abaxis, Inc. (NASDAQ: ABAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABAX stands at 0. In comparison, SCAI has a market cap of 0. Regarding current trading prices, ABAX is priced at $83.00 on the NASDAQ, while SCAI trades at $55.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABAX currently has a P/E ratio of 70.62, whereas SCAI's P/E ratio is 63.45. In terms of profitability, ABAX's ROE is +0.10%, compared to SCAI's ROE of +0.09%. Regarding short-term risk, ABAX is less volatile compared to SCAI. This indicates lower risk in terms of short-term price fluctuations for ABAX.Check SCAI's competition here
Landauer Inc. (NYSE: LDR)
ABAX vs LDR Comparison August 2026
Abaxis, Inc. (NASDAQ: ABAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABAX stands at 0. In comparison, LDR has a market cap of 0. Regarding current trading prices, ABAX is priced at $83.00 on the NASDAQ, while LDR trades at $67.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABAX currently has a P/E ratio of 70.62, whereas LDR's P/E ratio is N/A. In terms of profitability, ABAX's ROE is +0.10%, compared to LDR's ROE of +1.17%. Regarding short-term risk, ABAX is less volatile compared to LDR. This indicates lower risk in terms of short-term price fluctuations for ABAX.Check LDR's competition here
Mazor Robotics Ltd. (NASDAQ: MZOR)
ABAX vs MZOR Comparison August 2026
Abaxis, Inc. (NASDAQ: ABAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABAX stands at 0. In comparison, MZOR has a market cap of 0. Regarding current trading prices, ABAX is priced at $83.00 on the NASDAQ, while MZOR trades at $58.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABAX currently has a P/E ratio of 70.62, whereas MZOR's P/E ratio is -70.18. In terms of profitability, ABAX's ROE is +0.10%, compared to MZOR's ROE of -0.14%. Regarding short-term risk, ABAX is similarly volatile compared to MZOR. This indicates similar risk in terms of short-term price fluctuations for ABAX.Check MZOR's competition here
Med-Design Corp. (The) (NASDAQ: MEDC)
ABAX vs MEDC Comparison August 2026
Abaxis, Inc. (NASDAQ: ABAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABAX stands at 0. In comparison, MEDC has a market cap of 0. Regarding current trading prices, ABAX is priced at $83.00 on the NASDAQ, while MEDC trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABAX currently has a P/E ratio of 70.62, whereas MEDC's P/E ratio is N/A. In terms of profitability, ABAX's ROE is +0.10%, compared to MEDC's ROE of N/A. Regarding short-term risk, ABAX is less volatile compared to MEDC. This indicates lower risk in terms of short-term price fluctuations for ABAX.Check MEDC's competition here
St. Jude Medical, Inc. (NYSE: STJ)
ABAX vs STJ Comparison August 2026
Abaxis, Inc. (NASDAQ: ABAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABAX stands at 0. In comparison, STJ has a market cap of 0. Regarding current trading prices, ABAX is priced at $83.00 on the NASDAQ, while STJ trades at $80.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABAX currently has a P/E ratio of 70.62, whereas STJ's P/E ratio is 34.69. In terms of profitability, ABAX's ROE is +0.10%, compared to STJ's ROE of +0.21%. Regarding short-term risk, ABAX is less volatile compared to STJ. This indicates lower risk in terms of short-term price fluctuations for ABAX.Check STJ's competition here
LifePoint Health, Inc. (NASDAQ: LPNT)
ABAX vs LPNT Comparison August 2026
Abaxis, Inc. (NASDAQ: ABAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABAX stands at 0. In comparison, LPNT has a market cap of 0. Regarding current trading prices, ABAX is priced at $83.00 on the NASDAQ, while LPNT trades at $64.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABAX currently has a P/E ratio of 70.62, whereas LPNT's P/E ratio is 67.44. In terms of profitability, ABAX's ROE is +0.10%, compared to LPNT's ROE of +0.05%. Regarding short-term risk, ABAX is similarly volatile compared to LPNT. This indicates similar risk in terms of short-term price fluctuations for ABAX.Check LPNT's competition here
Cynosure, Inc. (NASDAQ: CYNO)
ABAX vs CYNO Comparison August 2026
Abaxis, Inc. (NASDAQ: ABAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABAX stands at 0. In comparison, CYNO has a market cap of 0. Regarding current trading prices, ABAX is priced at $83.00 on the NASDAQ, while CYNO trades at $66.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABAX currently has a P/E ratio of 70.62, whereas CYNO's P/E ratio is 105.35. In terms of profitability, ABAX's ROE is +0.10%, compared to CYNO's ROE of +0.03%. Regarding short-term risk, ABAX is less volatile compared to CYNO. This indicates lower risk in terms of short-term price fluctuations for ABAX.Check CYNO's competition here
Pharmerica Corporation (NYSE: PMC)
ABAX vs PMC Comparison August 2026
Abaxis, Inc. (NASDAQ: ABAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABAX stands at 0. In comparison, PMC has a market cap of 0. Regarding current trading prices, ABAX is priced at $83.00 on the NASDAQ, while PMC trades at $29.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABAX currently has a P/E ratio of 70.62, whereas PMC's P/E ratio is 47.95. In terms of profitability, ABAX's ROE is +0.10%, compared to PMC's ROE of +0.04%. Regarding short-term risk, ABAX is less volatile compared to PMC. This indicates lower risk in terms of short-term price fluctuations for ABAX.Check PMC's competition here
Envision Healthcare Corporation (NYSE: EVHC)
ABAX vs EVHC Comparison August 2026
Abaxis, Inc. (NASDAQ: ABAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABAX stands at 0. In comparison, EVHC has a market cap of 0. Regarding current trading prices, ABAX is priced at $83.00 on the NASDAQ, while EVHC trades at $45.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABAX currently has a P/E ratio of 70.62, whereas EVHC's P/E ratio is -3.20. In terms of profitability, ABAX's ROE is +0.10%, compared to EVHC's ROE of +0.07%. Regarding short-term risk, ABAX is less volatile compared to EVHC. This indicates lower risk in terms of short-term price fluctuations for ABAX.Check EVHC's competition here
Cotiviti Holdings, Inc. (NYSE: COTV)
ABAX vs COTV Comparison August 2026
Abaxis, Inc. (NASDAQ: ABAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABAX stands at 0. In comparison, COTV has a market cap of 0. Regarding current trading prices, ABAX is priced at $83.00 on the NASDAQ, while COTV trades at $44.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABAX currently has a P/E ratio of 70.62, whereas COTV's P/E ratio is 26.51. In terms of profitability, ABAX's ROE is +0.10%, compared to COTV's ROE of +0.14%. Regarding short-term risk, ABAX is less volatile compared to COTV. This indicates lower risk in terms of short-term price fluctuations for ABAX.Check COTV's competition here
AmSurg Corp (NASDAQ: AMSG)
ABAX vs AMSG Comparison August 2026
Abaxis, Inc. (NASDAQ: ABAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABAX stands at 0. In comparison, AMSG has a market cap of 0. Regarding current trading prices, ABAX is priced at $83.00 on the NASDAQ, while AMSG trades at $67.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABAX currently has a P/E ratio of 70.62, whereas AMSG's P/E ratio is N/A. In terms of profitability, ABAX's ROE is +0.10%, compared to AMSG's ROE of +0.08%. Regarding short-term risk, ABAX is less volatile compared to AMSG. This indicates lower risk in terms of short-term price fluctuations for ABAX.Check AMSG's competition here
Spectranetics Corp. (The) (NASDAQ: SPNC)
ABAX vs SPNC Comparison August 2026
Abaxis, Inc. (NASDAQ: ABAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABAX stands at 0. In comparison, SPNC has a market cap of 0. Regarding current trading prices, ABAX is priced at $83.00 on the NASDAQ, while SPNC trades at $38.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABAX currently has a P/E ratio of 70.62, whereas SPNC's P/E ratio is -24.03. In terms of profitability, ABAX's ROE is +0.10%, compared to SPNC's ROE of -0.61%. Regarding short-term risk, ABAX is less volatile compared to SPNC. This indicates lower risk in terms of short-term price fluctuations for ABAX.Check SPNC's competition here
Derma Sciences, Inc. (NASDAQ: DSCI)
ABAX vs DSCI Comparison August 2026
Abaxis, Inc. (NASDAQ: ABAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABAX stands at 0. In comparison, DSCI has a market cap of 0. Regarding current trading prices, ABAX is priced at $83.00 on the NASDAQ, while DSCI trades at $7.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABAX currently has a P/E ratio of 70.62, whereas DSCI's P/E ratio is -0.02. In terms of profitability, ABAX's ROE is +0.10%, compared to DSCI's ROE of -0.00%. Regarding short-term risk, ABAX is less volatile compared to DSCI. This indicates lower risk in terms of short-term price fluctuations for ABAX.Check DSCI's competition here
Span-America Medical Systems, Inc. (NASDAQ: SPAN)
ABAX vs SPAN Comparison August 2026
Abaxis, Inc. (NASDAQ: ABAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABAX stands at 0. In comparison, SPAN has a market cap of 0. Regarding current trading prices, ABAX is priced at $83.00 on the NASDAQ, while SPAN trades at $29.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABAX currently has a P/E ratio of 70.62, whereas SPAN's P/E ratio is N/A. In terms of profitability, ABAX's ROE is +0.10%, compared to SPAN's ROE of +0.17%. Regarding short-term risk, ABAX is less volatile compared to SPAN. This indicates lower risk in terms of short-term price fluctuations for ABAX.Check SPAN's competition here
Exactech, Inc. (NASDAQ: EXAC)
ABAX vs EXAC Comparison August 2026
Abaxis, Inc. (NASDAQ: ABAX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABAX stands at 0. In comparison, EXAC has a market cap of 0. Regarding current trading prices, ABAX is priced at $83.00 on the NASDAQ, while EXAC trades at $49.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABAX currently has a P/E ratio of 70.62, whereas EXAC's P/E ratio is 3510.33. In terms of profitability, ABAX's ROE is +0.10%, compared to EXAC's ROE of +0.00%. Regarding short-term risk, ABAX is similarly volatile compared to EXAC. This indicates similar risk in terms of short-term price fluctuations for ABAX.Check EXAC's competition here